We performed a narrative synthesis of preclinical and clinical evidence on OPN across three domains: (i) VAT biology and senescence‐associated secretory phenotype (SASP); (ii) atherosclerosis and plaque vulnerability; and (iii) myocardial fibrosis/remodelling and cardiometabolic heart failure. The gene discussed is SPP1; the disease is Myocardial fibrosis.